Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive September 1, 2010	Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development.
Bio-IT World May 9, 2003 Michael Greeley	Mechanistic Models Investors are backing predictive modeling software that could speed drug development.
Chemistry World August 23, 2012 Simon Campbell	Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.
Pharmaceutical Executive October 1, 2011 Daniel Vasella	Heart of Success: Patient-Centric R&D Drug discovery must remain a core competency of industry. The future success of individual companies will be tightly linked to success in R&D.
Bio-IT World June 17, 2004 Michael A. Greeley	A Bet on Biomarkers Biomarkers are a hot topic among venture capitalists these days and while they are becoming increasingly important in drug discovery and delivery processes, there is great debate about the best business models for marketing the related tools.
Pharmaceutical Executive April 1, 2007 Walter Armstrong	Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom.
Pharmaceutical Executive January 21, 2014 Tim Powell	Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way?
Pharmaceutical Executive October 1, 2005 Mark J. Ahn	It's All Academic: Biotechs Looking to Universities Pharmaceuticals and academic institutions are forming alliances at an increasing rate to exploit the promise of emerging biological insights.
Bio-IT World December 10, 2002 Jim Hall	21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives.
Pharmaceutical Executive June 1, 2005 Jan Malek	When Two Heads are Better R&D president isn't one job-it's two. By appointing COOs for R&D with broad operational mandates, biotech and pharmaceutical companies can ensure that operational issues get the attention they urgently require.
Bio-IT World July 11, 2002 Kevin Davies	Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go.
Bio-IT World April 2007 Malorye Allison	Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines?
Pharmaceutical Executive January 1, 2009 Stan Bernard	Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms.
Bio-IT World June 12, 2002 Morris R. Levitt	A New Economic Paradigm for Bio-IT? All who work in the bio-IT industry -- scientists, IT and informatics managers, and executives -- have been aware for some time that we seem to be suspended between an acute sense of crisis and a field of boundless opportunity.
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.
Pharmaceutical Executive January 1, 2012 William Looney	Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Pharmaceutical Executive May 1, 2009	Ad(Ventures) in Pharmaland Despite the downside in ad spend, an upside remains in the digital space that's wide open for exploration.
Pharmaceutical Executive June 1, 2012	2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead.
Chemistry World July 25, 2008 Sarah Houlton	Small is beautiful for GSK drug discovery New GlaxoSmithKline chief executive Andrew Witty is restructuring the firm's drug discovery, setting up small, highly focussed research teams that will have to bid for funding.
Pharmaceutical Executive January 1, 2012 Jill Wechsler	New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation.
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
Pharmaceutical Executive July 3, 2007 Humphrey Taylor	Opinion: Lead, Follow, or Get Out of the Way A comparative-effectiveness board is coming. The pharmaceutical industry's wise will embrace the change.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Chemistry World December 6, 2012 Andrew Turley	Return on drug R&D dropping The pharma industry is getting less and less return on investment in R&D, according to a report. But the trend seems to be bottoming out and -- on a more positive note -- there are more compounds going into late stage development.
Pharmaceutical Executive September 1, 2011 Richard Barker	Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
Pharmaceutical Executive October 1, 2005 Brad Miles	Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies.
Bio-IT World September 2005 Michael A. Greeley	Harvesting Patient Data Longitudinal data tools will allow pharmaceuticals to optimize sales force deployments and distribution strategies based on medical impacts of their compounds across various population sets.
Pharmaceutical Executive July 30, 2007 Stewart Young	Marketing to Professionals: The Essence of a Brand Beyond good messaging, marketers must establish a brand that is forever etched into physicians' minds.
Bio-IT World September 11, 2003	Show Me the Evidence ... Some emerging bio-IT services companies are beginning to attract venture capital.
Pharmaceutical Executive July 30, 2007	Direct to Consumer: Creativity Through Understanding Creative consumer campaigns begin with a clear understanding of pharma rules and regulations.
Bio-IT World September 2006 Kevin Davies	The $2 Billion Pill? Challenges and opportunities facing the drug industry were recurring themes in the quartet of keynote speeches at the 2006 Drug Discovery Technology conference.
BusinessWeek October 4, 2004	"It's a Perfect Storm" for Drugmakers Glaxo CEO Jean-Pierre Garnier answers questions about the biotech industry's hardships and how his company is improving its search for new drugs
Bio-IT World January 21, 2005 Jim Golden	Top 10 Trends for 2005 Pharmacovigilance, compliance, outsourcing, and the CIO's role will be big this year.
Bio-IT World December 10, 2002 Malorye Branca	The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D.
Pharmaceutical Executive October 1, 2010	When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve?
Bio-IT World Dec 2005/Jan 2006 Michael A. Greeley	Infinite Demand for the Unavailable The bio-IT field is once again attracting venture capital, but at a more moderate, deliberate pace than the euphoria of the late 1990s.
Pharmaceutical Executive June 1, 2007 Stan Bernard	Consumerization: Pandora's Pillbox By going direct-to-consumer, the industry unwittingly unleashed a swarm of opportunities for other players to enter the pharmaceutical fray. And they made the most of it. Now, a decade later, pharma is feeling the fallout in consumer trust and product value. It's time to take back control.
Pharmaceutical Executive November 1, 2011 William Looney	R&D Costs: It's Industry's Problem If high prices that lower access are attributable to a flawed R&D model, can the pharmaceutical industry embrace delivering better results at lower costs.
Pharmaceutical Executive May 1, 2007 Diane West	Spend Trends 2007: Hang 10 Direct-to-Consumer Advertising Hits Its First Decade: Dr. Dot-Com... Digital Detailing... etc.
Pharmaceutical Executive December 1, 2005 Patrick Clinton	PharmExec's 2006 Forecast The 2006 pharmaceutical industry is under assault from Congress, the press and the public, add a complex government program that will unimaginably change industry economics, and subtract revenues from off-patent products.
Pharmaceutical Executive May 1, 2007	Thoughtleader: Thomas Nagle, Strategic Pricing Group This industry consultant believes the U.S. government will soon follow Europe's lead in taking a greater hand in price negotiations, and pharma will need to be able to communicate the value that products offer. Here he discusses how pharma can meet that challenge.
Pharmaceutical Executive July 30, 2007 Peter Pitts	Opinion: Fewer Cents, More Sense Our healthcare system may be broken, but playing the blame game is not going to fix it. Remember that disease - not Big Pharma - is the enemy.
Bio-IT World July 14, 2004	The True Cost of Drug Discovery A new book with the provocative title "The $800 Million Pill" threatens to "strip away pharmaceutical industry spin" about the true cost of drug development.
Pharmaceutical Executive July 3, 2007	Direct to Consumer: The Secret of My Success Pharmaceutical industry experts sound off on the methods behind an award-winning ad and how the next great direct-to-consumer campaign will come about.
Pharmaceutical Executive July 3, 2007	Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work.
Pharmaceutical Executive June 1, 2007 Michael Goodman	A Very Specialty Moment Big Pharma is on a shopping spree for biologics and other specialty products. It has the money to buy them. But does it have the mojo to develop and market them successfully - or will the mid-size biopharmas make their big move?
Pharmaceutical Executive January 1, 2007 Glass & Poli	Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges.
Bio-IT World July 2005 Michael A. Greeley	CEO Lessons on Product and Market In the face of extraordinary R&D budgets generated by biopharma industries, bio-IT companies must refine their value propositions in the hopes that meaningful (predictable and repeatable) revenue streams can be created.
Pharmaceutical Executive September 1, 2008 Sarah Houlton	Doing More With Less In order to take a big step forward, GlaxoSmithKline looks to employ smaller licensing deals and business units.
Pharmaceutical Executive October 1, 2005 Jill Van Den Bos	Formulary Additions: The Big Picture Product managers at pharma firms know how fiercely new drugs compete for inclusion on health plans' formularies. An actuarially sound, full-budget-impact model may be out of reach. But companies could express data in units that a health plan can integrate into its own internal actuarial analysis.